Intercept platelet processing set
Ended Purchase Order Awarded Last action
- Contract number
- N6264520P0024
- Awardee
-
Cerus Corporation UEI KJJQRRLY2FL5
- Awarding agency
-
Bureau of Medicine and Surgery
Department of the Navy, Department of Defense
- Obligated
- $56,160
Award facts
- Opportunity
-
- CERUS INTERCEPT-Blood Products Pre-Solicitation · N6264520R0022 · Posted Feb 6, 2020
- CERUS INTERCEPT-Blood Products Award Notice · Posted May 13, 2020
- CERUS INTERCEPT-Blood Products Limited / Sole Source Justification · Posted May 13, 2020
- Contract value 19% obligated
-
- $233,364.00 Current, with exercised options
- $295,380.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- France
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $60,534 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $59,064 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $57,606 | |
| Original award | $56,160 |
About this award
On May 13, 2020, the Bureau of Medicine and Surgery (BUMED), a defense agency within the Department of the Navy, awarded a firm fixed-price purchase order to Cerus Corporation valued at $295,380 for the supply of INTERCEPT Platelet Processing Sets. The contract, which has an ultimate completion date of May 12, 2025, supports an existing pathogen reduction system at the United States Naval Hospital in Guam. Under this sole-source award, Cerus will provide INTERCEPT platelet small volume processing sets, INTERCEPT platelet processing sets with dual storage containers, shipping services, and two annual technical service representative visits. The place of performance is France, reflecting Cerus Corporation's manufacturing and distribution operations. No set-aside designation was used for this procurement.
Cerus Corporation, a biomedical products manufacturer headquartered in Concord, California, is the sole provider of the proprietary INTERCEPT Blood System technology, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. The sole-source award reflects Cerus's unique technological capabilities in pathogen reduction systems for blood safety, making the company the incumbent supplier for this critical medical application. The originating solicitation indicated an estimated five-year contract value of $5 million to $10 million across multiple option years, with this purchase order representing the initial contract action supporting the Naval Medical Logistics Command's requirement for enhanced transfusion safety at naval medical facilities.
Quick answers
Who was awarded contract N6264520P0024?
N6264520P0024 was awarded to Cerus Corporation by Bureau of Medicine and Surgery (Department of the Navy) on May 13, 2020.
How much is contract N6264520P0024 worth?
The government has obligated $56,160 on N6264520P0024. Its current value, with exercised options, is $233,364. Its potential value, with all options, is $295,380.
Was contract N6264520P0024 competed?
The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award